Advisory Services Network LLC Sells 2,913 Shares of DexCom, Inc. (NASDAQ:DXCM)

Advisory Services Network LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 51.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,785 shares of the medical device company’s stock after selling 2,913 shares during the quarter. Advisory Services Network LLC’s holdings in DexCom were worth $217,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the period. TD Private Client Wealth LLC lifted its holdings in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC grew its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $38,000. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several analyst reports. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price target on the stock. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Canaccord Genuity Group lifted their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.00.

DexCom Stock Down 0.2 %

DXCM stock opened at $68.59 on Friday. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The stock has a market cap of $26.90 billion, a P/E ratio of 47.97, a P/E/G ratio of 2.30 and a beta of 1.50. The stock’s fifty day simple moving average is $74.98 and its two-hundred day simple moving average is $76.67. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 over the last ninety days. 0.32% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.